Clinical Trial Update: Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating full- and half-dose tenecteplase (TNK-tPA) with different anticoagulants in acute myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Abciximab (abciximab)
• Enoxaparin (enoxaparin sodium)
• HEPARIN SODIUM (HEPARIN SODIUM)
• Tenecteplase (TNK-tPA) (tenecteplase)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Myocardial Infarction | Phase 3 | Status: COMPLETED